Safety and tolerability of a high-potency zoster vaccine in adults ≥50 years of age

Vaccine

Volumn 25, Issue 10, 2007, Pages 1877-1883

  Tyring, Stephen K ^a   Diaz Mitoma, Francisco ^b   Padget, Larry G ^c   Nunez, Margarita ^d   Poland, Gregory ^e   Cassidy, William M ^f   Bundick, Nickoya D ^g   Li, Jianjun ^g   Chan, Ivan S F ^g   Stek, Jon E ^g   Annunziato, Paula W ^g  

^a UNIVERSITY OF TEXAS   (United States)

^b CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^c GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^d CNS Clinical Trials   (United States)

^e MAYO CLINIC   (United States)

^f LOUISIANA STATE UNIVERSITY   (United States)

^g MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Safety; Tolerability; Zoster vaccine

Indexed keywords

VARICELLA ZOSTER VACCINE;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEPRESSION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; ENTERITIS; FEMALE; HERPES ZOSTER; HUMAN; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; POLYMERASE CHAIN REACTION; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VARICELLA ZOSTER VIRUS;

AGED; AGED, 80 AND OVER; DOUBLE-BLIND METHOD; EDEMA; FEMALE; HERPES ZOSTER; HERPES ZOSTER VACCINE; HUMANS; MALE; MIDDLE AGED; PAIN;

EID: 33846582989     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.10.027     Document Type: Article

References (29)

1. Hope-Simpson R.E. Postherpetic neuralgia. J R Coll Gen Pract 25 (1975) 571-575
2. Gnann Jr. J.W., and Whitley R.J. Herpes zoster. N Engl J Med 347 (2002) 340-346
3. Brisson M., and Edmunds W.J. Epidemiology of Varicella-Zoster Virus in England and Wales. J Med Virol 70 (2003) S9-S14
4. Opstelten W., Mauritz J.W., de Wit N.J., van Wijck A.J.M., Stalman W.A.B., and van Essen G.A. Herpes zoster and postherpetic neuralgia: incidence and risk indicators using a general practice research database. Fam Pract 19 (2002) 471-475
5. di Luzio Paparatti U., Arpinelli F., and Visoná G. Herpes zoster and its complications in Italy: an observational survey. J Infect 38 (1999) 116-119
6. Law BJ, Chateau D, Walld R, Roos LL. Temporal trends in the annual population-based incidence of herpes zoster by age and gender: Manitoba, 1979-1998 [poster]. 6th Canadian Immunization Conference, 2004 Dec 5-8. Montreal, Québec, Canada 2004.
7. Donahue J.G., Choo P.W., Manson J.E., and Platt R. The incidence of herpes zoster. Arch Intern Med 155 (1995) 1605-1609
8. Insinga R.P., Itzler R.F., Pellisier J.M., Saddier P., and Nikas A.A. The incidence of herpes zoster in a United States administrative database. J Gen Intern Med 20 August (8) (2005) 748-753
9. Schmader K. Herpes zoster in older adults. Clin Infect Dis 32 (2001) 1481-1486
10. Straus S.E., Ostrove J.M., Inchauspé G., Felser J.M., Freifeld A., Croen K.D., et al. Varicella-zoster virus infections: biology, natural history, treatment, and prevention [NIH Conference]. Ann Intern Med 108 (1988) 221-237
11. Dworkin R.H., and Schmader K.E. The epidemiology and natural history of herpes zoster and postherpetic neuralgia. In: Watson C.P., and Gershon A.A. (Eds). Herpes Zoster and Postherpetic Neuralgia. 2nd revised and enlarged ed. 11 (2001), Elsevier Science B.V., Amsterdam, The Netherlands 39-64
12. Burgoon Jr. C.F., Burgoon J.S., and Bladridge G.D. The natural history of herpes zoster. JAMA 164 3 (1957) 265-269
13. Brisson M., Edmunds W.J., Law B., Gay N.J., Walld R., Brownell M., et al. Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiol Infect 127 (2001) 305-314
14. Hope-Simpson R.E. The nature of herpes zoster: a long-term study and a new hypothesis (section of general practice). Proc R Soc Med 58 (1965) 9-20
15. Watson C.P.N., Watt V.R., Chipman M., Birkett N., and Evans R.J. The prognosis with postherpetic neuralgia. Pain 46 (1991) 195-199
16. Kost R.G., and Straus S.E. Postherpetic neuralgia-pathogenesis, treatment, and prevention. N Engl J Med 335 1 (1996) 32-42
17. Jung B.F., Johnson R.W., Griffin D.R.J., and Dworkin R.H. Risk factors for postherpetic neuralgia in patients with herpes zoster. Neurology 62 (2004) 1545-1551
18. Crooks R.J., Jones D.A., and Fiddian A.P. Zoster-associated chronic pain: an overview of clinical trials with acyclovir. Scand J Infect Dis 78 Suppl (1991) 62-68
19. Bowsher D. The lifetime occurrence of herpes zoster and prevalence of post-herpetic neuralgia: a retrospective survey in an elderly population. Eur J Pain 3 (1999) 335-342
20. Wood M.J., Ogan P.H., McKendrick M.W., Care C.D., McGill J.I., and Webb E.M. Efficacy of oral acyclovir treatment of acute herpes zoster. Am J Med 85 Suppl 2A (1988) 79-83
21. Schmader K.E., and Studenski S. Are current therapies useful for the prevention of postherpetic neuralgia: a critical analysis of literature. J Gen Intern Med 4 (1989) 83-89
22. Huff J.C., Bean B., Balfour H.H., Laskin O.L., Connor J.D., Corey L., et al. Therapy of herpes zoster with oral acyclovir. Am J Med 85 Suppl 2A (1988) 84-89
23. Morton P., and Thomson A.N. Oral acyclovir in the treatment of herpes zoster in general practice. NZ Med J 102 863 (1989) 93-95
24. Tyring S., Barbarash R.A., Nahlik J.E., Cunningham A., Marley J., Heng M., et al. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 123 2 (1995) 89-96
25. Argoff C.E., Katz N., and Backonja M. Treatment of postherpetic neuralgia: a review of therapeutic options. J Pain Symptom Manage 28 4 (2004) 396-411
26. Johnson R.W., and Whitton T.L. Management of herpes zoster (shingles) and postherpetic neuralgia. Expert Opin Pharmacother 5 3 (2004) 551-559
27. Goh C.-L., and Khoo L. A retrospective study of the clinical presentation and outcome of herpes zoster in a tertiary dermatology outpatient referral clinic. Int J Dermatol 36 (1997) 667-672
28. Oxman M.N., Levin M.J., Johnson G.R., Schmader K.E., Straus S.E., Gelb L.D., et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 352 (2005) 2271-2284
29. Merck Research Laboratories Clinical Study Report for PNEUMOVAX™ 23 Protocol 009 [data on file]. Whitehouse Station, NJ: Merck & Co., Inc.; 2002.